A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Authors:
Open Access
- 10 May 2019
- journal article
- research article
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 39 (5)
Abstract
Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases. TNBC is highly aggressive and associated with poor prognosis. The present study aimed to compare gene expression between TNBC patients with pathological complete response (pCR) and those with not complete response (nCR) to neoadjuvant chemotherapy. Microarray data of 16 TNBC patients received neoadjuvant chemotherapy were identified from the Gene Expression Omnibus database and 10 patients of them had pCR. We found that 250 coding genes and 155 long noncoding RNAs (lncRNAs) were statistically differentially expressed between patients with pCR and nCR. Receiver operator characteristic curve and area under the curve (AUC) were calculated to assess predictive value of differentially expressed genes. A gene signature of three coding genes and two lncRNA was developed: 2.318*TCF3 + 7.349*CREB1 + 0.891*CEP44 + 0.091*NR_023392.1 + 1.424*NR_048561.1 − 106.682. The gene signature was further validated and had an AUC = 0.829. In summary, we profiled gene expression in pCR patients and developed a gene signature, which was effective to predict pCR among TNBC patients received neoadjuvant chemotherapy.Keywords
This publication has 29 references indexed in Scilit:
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis toolBMC Bioinformatics, 2013
- cAMP Responsive Element Binding Protein-1 Is a Transcription Factor of Lysosomal-Associated Protein Transmembrane-4 beta in Human Breast Cancer CellsPLOS ONE, 2013
- Molecular Basis of Triple Negative Breast Cancer and Implications for TherapyInternational Journal of Breast Cancer, 2011
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?Annals of Oncology, 2010
- Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasisNature, 2010
- CREB in the Pathophysiology of Cancer: Implications for Targeting Transcription Factors for Cancer TherapyClinical Cancer Research, 2009
- Evolution and Functions of Long Noncoding RNAsCell, 2009
- Diversity of LEF/TCF action in development and diseaseOncogene, 2006
- Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2006